| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 05/30/2012 | CN1919873B Fusion albumen containing HSP70 ATPase structure field and mammal p53 albumen and application thereof |
| 05/30/2012 | CN102483404A Process for the identification of compounds for treating cancer |
| 05/30/2012 | CN102482677A 通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)-样2(nrf2)相关疾病 By inhibiting nrf2 natural antisense transcripts treatment of nuclear factor (RBC-derived 2) - Sample 2 (nrf2) related diseases |
| 05/30/2012 | CN102482672A 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病 By suppressing natural antisense transcripts Down syndrome Down syndrome gene therapy gene-related diseases |
| 05/30/2012 | CN102482671A 通过抑制'含有gtp酶激活蛋白的iq模体'(iqgap)的天然反义转录物而治疗iqgap相关疾病 By inhibiting 'containing enzyme activator protein iq gtp motif' (iqgap) natural antisense transcript of treating diseases associated iqgap |
| 05/30/2012 | CN102482670A 通过抑制'hsp70-相互作用蛋白的c末端'(chip)的天然反义转录物而治疗chip相关疾病 By inhibiting 'hsp70- interacting protein c-terminal' (chip) of natural antisense transcripts and treat chip-related diseases |
| 05/30/2012 | CN102482664A Marker for predicting therapeutic effect on hepatitis c, method for predicting therapeutic effect on hepatitis c, and prophylaxis or therapeutic agent for hepatitis c |
| 05/30/2012 | CN102481379A 靶向pax2用于治疗乳腺癌 For the treatment of breast cancer targeted pax2 |
| 05/30/2012 | CN102481378A Hpv颗粒及其用途 Hpv particles and their use |
| 05/30/2012 | CN102481333A Immunity inducer |
| 05/30/2012 | CN102481256A 包含亚氨基脂质的两性脂质体 Amphoteric liposomes containing imino liposome |
| 05/30/2012 | CN102477440A 治疗基因在厌氧组织靶向递送和选择性稳定表达方法及应用 Targeted delivery of therapeutic gene expression and selective method and application of stability in anaerobic tissue |
| 05/30/2012 | CN102477439A 三元复合物和含有三元复合物的液体及制备方法与应用 Ternary complex and fluid, and preparation method and application containing ternary complexes |
| 05/30/2012 | CN102475893A Method for treating human malignant solid tumor by using hepatocyte nuclear factor-1alpha |
| 05/30/2012 | CN102475892A Application of anti-sense miRNA (Ribonucleic Acid)-210 to preparation of anti-cancer drug |
| 05/30/2012 | CN102091333B Application of miR-124 in preparation of medicines for preventing infectious shock |
| 05/30/2012 | CN101920021B Immune-enhanced hepatitis B therapeutic multivalent vaccine and preparation method thereof |
| 05/30/2012 | CN101886084B Codon-optimized H3HA/XJ3-07 gene and nucleic acid vaccine thereof |
| 05/30/2012 | CN101850124B Albumin nanometer-ultrasonic microbubble carrier tissue type plasminogen activator gene target system and preparation method thereof |
| 05/30/2012 | CN101792740B Recombinant baculovirus expressing Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) immunogen gene and preparation method and application thereof |
| 05/30/2012 | CN101748125B siRNA segment and application thereof used for curing and/or preventing Porcine Reproductive and Respiratory Syndrome |
| 05/30/2012 | CN101492711B Uses of MAGEA9 gene |
| 05/30/2012 | CN101259289B Methods and compositions for therapeutic use of RNA interference |
| 05/30/2012 | CN101148667B Preparation and use for affinity human albumin nucleic acid aptamer |
| 05/30/2012 | CN101148666B Nucleic acid adapter with high specificity and high affinity to human breast carcinoma tissue, preparation method and application thereof |
| 05/29/2012 | US8188264 RNAi mediated knockdown of NuMA for cancer therapy |
| 05/29/2012 | US8188259 Seven or more contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages; antisense agents for gene expression inhibition of a wide variety of pathological disorders such as autoimmune diseases; suitable for oral administration |
| 05/29/2012 | US8188254 C-class oligonucleotide analogs with enhanced immunostimulatory potency |
| 05/29/2012 | US8188250 Butanol dehydrogenase enzyme from the bacterium Achromobacter xylosoxidans |
| 05/29/2012 | US8188247 Conjugates and compositions for cellular delivery |
| 05/29/2012 | US8188246 Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use |
| 05/29/2012 | US8188228 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
| 05/29/2012 | US8188062 Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA |
| 05/29/2012 | US8188060 Duplex oligonucleotides with enhanced functionality in gene regulation |
| 05/29/2012 | US8188056 Utilizing nucleic acid expression constructs that are delivered into a subject and express stable therapeutic proteins in vivo |
| 05/29/2012 | US8187828 Use of PAK inhibitor for the treatment of a joint disease |
| 05/29/2012 | US8187615 Non-aqueous compositions for oral delivery of insoluble bioactive agents |
| 05/29/2012 | US8187600 Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses |
| 05/29/2012 | US8187598 Methods of treating cancer by administering antibodies to CD200 |
| 05/29/2012 | US8187587 Immunotherapeutic methods targeted toward stratum corneum chymotryptic enzyme |
| 05/29/2012 | US8187586 Methods of inducing apoptosis in hyperproliferative cells |
| 05/29/2012 | CA2514584C Peptide inhibitors of toxins derived from ll-37 |
| 05/29/2012 | CA2478616C Use of adenoviruses mutated in the va genes for cancer treatment |
| 05/29/2012 | CA2469623C Composition for the preservation of viruses |
| 05/29/2012 | CA2455403C Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses |
| 05/29/2012 | CA2440767C Novel neurotrophic factors |
| 05/29/2012 | CA2408786C Retroviral vectors comprising an enhanced 3' transcription termination structure |
| 05/29/2012 | CA2403985C Angiogenic onchocerca volvulus proteins and uses thereof |
| 05/29/2012 | CA2403817C Methods of modulating hair growth |
| 05/29/2012 | CA2395053C Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 05/29/2012 | CA2368855C Differentiation of monocytes into functional dendritic cells |
| 05/29/2012 | CA2280736C Methods for modulating hematopoiesis and vascular growth |
| 05/29/2012 | CA2268258C Single-chain multiple antigen-binding molecule, its preparation and use |
| 05/24/2012 | WO2012068463A2 Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt) |
| 05/24/2012 | WO2012068456A2 Compositions and methods for treating obesity |
| 05/24/2012 | WO2012068405A2 Modulation of alpha synuclein expression |
| 05/24/2012 | WO2012068344A2 Regulation of cathepsin l by its transcription factor dendrin |
| 05/24/2012 | WO2012068341A2 Wnt1 for treatment of cardiovascular disorders and injuries |
| 05/24/2012 | WO2012068340A2 Antagonat compositions and methods of use |
| 05/24/2012 | WO2012068295A1 Immunostimulatory oligonucleotides |
| 05/24/2012 | WO2012068176A1 Amine-containing transfection reagents and methods for making and using same |
| 05/24/2012 | WO2012068000A2 Methods of treating cancers with her3 and pik3ca antisense oligonucleotides |
| 05/24/2012 | WO2012067866A2 Multivalent vaccine for filariasis |
| 05/24/2012 | WO2012067839A2 Methods of treating neurodegenerative disease |
| 05/24/2012 | WO2012066171A1 Nanoparticles for the prevention and/or treatment of diseases of the mucus membranes |
| 05/24/2012 | WO2012046006A3 Cutaneous squamous cell carcinoma target sequences |
| 05/24/2012 | WO2012037043A8 Treatment of autoimmune inflammation using mir-155 |
| 05/24/2012 | WO2012011778A3 Cancer diagnosis kit and pharmaceutical composition for prevention or treatment of cancer |
| 05/24/2012 | WO2012009499A3 Assessing thyroid neoplasms and treating cancer |
| 05/24/2012 | WO2011142970A3 Her2 nucleic acid aptamers |
| 05/24/2012 | US20120130144 Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor |
| 05/24/2012 | US20120130046 Tropoelastin derivatives |
| 05/24/2012 | US20120129920 miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY |
| 05/24/2012 | US20120129919 Polycationic amphiphilic cyclooligosaccharides and the use thereof as molecular transporters |
| 05/24/2012 | US20120129918 Modified oligonucleotides for telomerase inhibition |
| 05/24/2012 | US20120129910 Inhibition of Apoptosis-Specific eIF-5A(elF-5A1") with Antisense Oligonucleotides and siRNA as Anti-Inflammatory Therapeutics |
| 05/24/2012 | US20120129776 Bioactive peptides and method of using same |
| 05/24/2012 | US20120129263 Recombinant viral vector for gene transfer into lymphoid cells |
| 05/24/2012 | US20120129184 Systemic carnitine deficiency gene and uses thereof |
| 05/24/2012 | US20120129178 Genomic polymorphism for predicting therapeutic response |
| 05/24/2012 | US20120128782 Multicomponent Degradable Cationic Polymers |
| 05/24/2012 | US20120128700 Constructs for delivery of therapeutic agents to neuronal cells |
| 05/24/2012 | US20120128635 Methods and compositions for treating hemophilia b |
| 05/24/2012 | US20120128594 Selective infarcted-tissue-targeting bacteria and use thereof |
| 05/24/2012 | US20120128586 Method for treating chronic lymphocytic leukemia |
| 05/24/2012 | CA2817960A1 Modulation of alpha synuclein expression |
| 05/23/2012 | EP2455471A2 Methods for treating hypercholesterolemia |
| 05/23/2012 | EP2455467A1 Double-stranded oligonucleotides |
| 05/23/2012 | EP2455466A1 Dna fragment and pharmaceutical composition |
| 05/23/2012 | EP2455065A1 Modified two-component gelation systems, methods of use and methods of manufacture |
| 05/23/2012 | EP2454372A2 Treatment and diagnosis of immune disorders |
| 05/23/2012 | EP2454368A1 Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance |
| 05/23/2012 | EP2453911A1 Immunogenic nanomedicine composition and preparation and uses thereof |
| 05/23/2012 | EP2453875A1 Emulsion activatable by ultrasounds and method for producing same |
| 05/23/2012 | EP2453871A1 Orally administered bacteria as vehicles for systemic delivery of agents |
| 05/23/2012 | EP2453735A2 Dual vector for inhibition of human immunodeficiency virus |
| 05/23/2012 | EP1833986B1 Determinants of sensitivity to chemotherapeutic agents |
| 05/23/2012 | EP1800289B1 Single -pass image warping system and method with anisotropic filtering |
| 05/23/2012 | EP1653807B1 Use of dermal micro organs |
| 05/23/2012 | EP1601374B2 Compositions and methods for diagnosing and treating an inflammation |